Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Free Cash Flow (2016 - 2025)

OptimizeRx's Free Cash Flow history spans 16 years, with the latest figure at $3.1 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 92.77% year-over-year to $3.1 million; the TTM value through Sep 2025 reached $11.6 million, up 743.66%, while the annual FY2024 figure was $4.6 million, 162.11% up from the prior year.
  • Free Cash Flow for Q3 2025 was $3.1 million at OptimizeRx, down from $4.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $4.6 million in Q2 2025 and bottomed at -$6.3 million in Q4 2023.
  • The 5-year median for Free Cash Flow is $1.4 million (2023), against an average of $1.1 million.
  • The largest annual shift saw Free Cash Flow tumbled 949.35% in 2023 before it soared 1913.91% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$1.4 million in 2021, then soared by 303.1% to $2.8 million in 2022, then plummeted by 324.71% to -$6.3 million in 2023, then soared by 101.52% to $95000.0 in 2024, then soared by 3213.68% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Free Cash Flow are $3.1 million (Q3 2025), $4.6 million (Q2 2025), and $3.8 million (Q1 2025).